Crovalimab + Placebo
Phase 1/2Active 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Hemoglobinuria, Nocturnal
Conditions
Paroxysmal Hemoglobinuria, Nocturnal
Trial Timeline
Nov 14, 2016 → Sep 30, 2026
NCT ID
NCT03157635About Crovalimab + Placebo
Crovalimab + Placebo is a phase 1/2 stage product being developed by Chugai Pharmaceutical for Paroxysmal Hemoglobinuria, Nocturnal. The current trial status is active. This product is registered under clinical trial identifier NCT03157635. Target conditions include Paroxysmal Hemoglobinuria, Nocturnal.
What happened to similar drugs?
0 of 20 similar drugs in Paroxysmal Hemoglobinuria, Nocturnal were approved
Approved (0) Terminated (4) Active (16)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03157635 | Phase 1/2 | Active |
Competing Products
20 competing products in Paroxysmal Hemoglobinuria, Nocturnal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 30 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Danicopan | AstraZeneca | Phase 3 | 47 |
| LNP023 | Novartis | Pre-clinical | 33 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 40 |
| iptacopan | Novartis | Phase 2 | 35 |
| LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Pre-clinical | 30 |
| Iptacopan | Novartis | Phase 3 | 40 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 40 |
| LNP023 | Novartis | Phase 3 | 47 |
| LFG316 + LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Crovalimab | Roche | Phase 3 | 44 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 40 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 33 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 27 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 29 |